[How to Classify and Evaluate Complementary and Alternative Medicines in Oncology]

Dtsch Med Wochenschr. 2017 Jun;142(12):873-881. doi: 10.1055/s-0042-111613. Epub 2017 Jun 21.
[Article in German]

Abstract

There are a vast number of complementary and alternative medicines (CAM) in oncology. Also patients' needs for information on these methods are growing. Helping patients to classify and evaluate CAM methods is a challenge. The Cancer Information Service at the German Cancer Research Center has developed a benefit-risk-assessment based on evidence-based medicine and individual patient traits: To rate a CAM's benefit, the scientific evidence and the patient's therapeutic goals have to be taken into account. To estimate its risks, both, the method itself and the patient's status of health must be considered.

Publication types

  • Review

MeSH terms

  • Antineoplastic Agents, Phytogenic / adverse effects
  • Antineoplastic Agents, Phytogenic / therapeutic use
  • Complementary Therapies / adverse effects
  • Complementary Therapies / classification*
  • Evidence-Based Medicine
  • Germany
  • Humans
  • Neoplasms / mortality
  • Neoplasms / therapy*
  • Outcome and Process Assessment, Health Care*
  • Patient Education as Topic
  • Plant Extracts / adverse effects
  • Plant Extracts / therapeutic use
  • Quality of Life
  • Randomized Controlled Trials as Topic
  • Risk Assessment
  • Survival Rate

Substances

  • Antineoplastic Agents, Phytogenic
  • Plant Extracts